Please note: Next Awareness Night is Nov. 14.

Success of abiraterone trials prompts ‘mind shift’ in prostate cancer treatment

by Jim Barney on November 5, 2017

Share

Abiraterone acetate is poised to challenge docetaxel as the standard addition to androgen deprivation therapy for treatment of newly diagnosed, metastatic castration-resistant prostate cancer.

Read the article here.

{ 0 comments… add one now }

Previous post:

Next post: